These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


302 related items for PubMed ID: 9586913

  • 1. New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen.
    Westeel V, Murray N, Gelmon K, Shah A, Sheehan F, McKenzie M, Wong F, Morris J, Grafton C, Tsang V, Goddard K, Murphy K, Parsons C, Amy R, Page R.
    J Clin Oncol; 1998 May; 16(5):1940-7. PubMed ID: 9586913
    [Abstract] [Full Text] [Related]

  • 2. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S.
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [Abstract] [Full Text] [Related]

  • 3. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D.
    J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N.
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, Kakolyris S, Bania E, Jordanoglou J, Agelidou M, Vlachonicolis J, Georgoulias V, Greek Lung Cancer Cooperative Group.
    Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
    [Abstract] [Full Text] [Related]

  • 12. Influence of age on the treatment of limited-stage small-cell lung cancer.
    Siu LL, Shepherd FA, Murray N, Feld R, Pater J, Zee B.
    J Clin Oncol; 1996 Mar; 14(3):821-8. PubMed ID: 8622030
    [Abstract] [Full Text] [Related]

  • 13. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK, Nicaise C, Lawson R, Maroun JA, Comis R, Speer J, Luedke D, Hurtubise M, Lanzotti V, Goodlow J.
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [Abstract] [Full Text] [Related]

  • 14. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
    Johnson DH, Bass D, Einhorn LH, Crawford J, Perez CA, Bartolucci A, Omura GA, Greco FA.
    J Clin Oncol; 1993 Jul; 11(7):1223-9. PubMed ID: 8391064
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S, Norwegian Lung Cancer Study Group.
    J Clin Oncol; 2002 Dec 15; 20(24):4665-72. PubMed ID: 12488411
    [Abstract] [Full Text] [Related]

  • 16. Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study.
    Urtasun RC, Palmer M, Kinney B, Belch A, Hewitt J, Hanson J.
    Int J Radiat Oncol Biol Phys; 1998 Jan 15; 40(2):337-42. PubMed ID: 9457818
    [Abstract] [Full Text] [Related]

  • 17. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R, Flechtner H, Goerg R, Becker H.
    Semin Oncol; 1989 Feb 15; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [Abstract] [Full Text] [Related]

  • 18. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov 15; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS.
    Clin Lung Cancer; 2003 Jul 15; 5(1):40-5. PubMed ID: 14596703
    [Abstract] [Full Text] [Related]

  • 20. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
    Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A.
    J Clin Oncol; 2006 May 01; 24(13):2038-43. PubMed ID: 16648503
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 16.